Éric Raymond

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

Éric Raymond, Laëtitia Dahan, Jean‐Luc Raoul et al. · New England Journal of Medicine · 2011 · 2.5K citations

Medicine, Oncology, Pharmacology +11

EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer

Josep M. Llovet, Michel Ducreux, Riccardo Lencioni et al. · 2012 · 1.5K citations

Medicine, Oncology, Radiation Oncology +17

Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer

Sandrine Faivre, Catherine Delbaldo, Karina Vera et al. · Journal of Clinical Oncology · 2005 · 1.2K citations · Full text

Pharmacy, Oncology, Pharmacology +17

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types

José Baselga, Danny Rischin, Malcolm Ranson et al. · Journal of Clinical Oncology · 2002 · 831 citations

Medicine, Oncology, Pharmacology +16

Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial

Ann‐Lii Cheng, Yoon‐Koo Kang, Deng‐Yn Lin et al. · Journal of Clinical Oncology · 2013 · 774 citations · Full text

Medicine, Oncology, Pharmacology +15